Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

Completed · Phase 1

Conditions studied: Opioid-Related Disorders

In brief

To determine the pharmacokinetics of 2 intranasal doses and 1 oral dose of naltrexone compared to an intramuscular dose of naltrexone.

Key facts

Study ID

NCT02750748

Run by

National Institute on Drug Abuse (NIDA)

People needed

14

Starts

2016-07-01

Expected to finish

2016-09-01

Last updated by the study team

2017-01-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males and females 18 to 55 years of age, inclusive.
• Provide written informed consent.
• BMI ranging from 18 to 30 kg/m2, inclusive.
• Adequate venous access.
• No clinically significant concurrent medical conditions determined by medical history, physical examination, clinical laboratory examination, vital signs, and 12-lead ECG.
• Male subjects must agree to use an acceptable method of contraception with female partners as well as not to donate sperm throughout the study and for 90 days after the last study drug administration. Female subject of childbearing potential must agree to use an acceptable method of birth control throughout the study and for 30 days after the last study drug administration. Oral contraceptives are prohibited.
• Agree not to ingest alcohol, drinks containing xanthine >500 mg/day (e.g., Coca Cola®, coffee, tea, etc.), or grapefruit/grapefruit juice.
• Participate in strenuous exercise 72 hours prior to admission through the last blood draw of the study.

You may not qualify if…

• Please contact site for more information

Where it is running

• Vince and Associates Clinical Research, Inc. — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.